|Page (1) of 1 - 06/05/18||email article||print page|
Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO(June 05, 2018)
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that positive data from the SL-701 and SL-801 clinical trials were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL. The presentations are available on Stemline’s website (www.stemline.com) under the Scientific Presentations tab.
SL-701 – Clinical Highlights
- The Phase 2 trial of SL-701 in previously treated GBM patients met its primary endpoint of 12-month overall survival (OS-12)
Source:Copyright (c) GlobeNewswire, Inc. All Rights Reserved